Trial Profile
A Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisolone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 08 Jun 2009 New trial record.